Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OLX703A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg).
Product Name : OLX703A
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : OLX703A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : OliX Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement